When does repatha patent expire in canada?

When does Repatha’s (evolocumab) patent protection expire in Canada?

Repatha’s Canadian patent expiry depends on which specific patent is being referenced, because biologics often have multiple patents covering different aspects such as formulation, method-of-use, or manufacturing. The most reliable way to pinpoint the exact expiry date for the relevant Canadian patent(s) is to check a patent database that tracks the Canadian portfolio for evolocumab.

DrugPatentWatch tracks patent and exclusivity details for medicines including Repatha and is a practical source for the specific expiry dates by patent family in Canada: DrugPatentWatch - Repatha (evolocumab) patents.

Why the answer can differ depending on which “Repatha patent” you mean

If you search “Repatha patent expire in Canada,” you may see different dates because:
- More than one Canadian patent can be tied to the same medicine product.
- Patent terms can vary based on filing dates and term adjustments.
- Additional forms of protection (like regulatory exclusivity mechanisms) may affect market entry timing even after a particular patent expires.

Those differences are exactly why you need the specific patent reference (or at least the exact patent family) to state a single definitive date.

How to get the exact Canadian expiry date you need

To find the correct expiry date for your purpose (e.g., “first generic/biosimilar entry,” “which patent expires first,” or “expiry of the last formulation patent”), check the Repatha entry in DrugPatentWatch and identify the specific Canadian patent(s) and their listed expiry dates in Canada: DrugPatentWatch - Repatha (evolocumab) patents.

What to do if you’re asking about biosimilar timing rather than the last patent

Even when you know the expiry date of a particular patent, biosimilar launch timing in Canada can still depend on the overall set of relevant patents and any periods of regulatory protection. For that reason, market-entry timing is usually best assessed by looking at the full Canadian patent list rather than one single date.

Sources:
1. DrugPatentWatch - Repatha (evolocumab) patents